AIDS Therapies

Data on HIV Entry Inhibitors Presented

Published in AIDS Weekly, December 25th, 2000

Progenics Pharmaceuticals, Inc. (PGNX), St. Lucia, West Indies, reported findings on the company's anti-HIV agents PRO 542 and PRO 140.

The results were described at the Collaborative Research Seminar on HIV Entry and Fusion Inhibitors. HIV entry inhibitors are viewed as a promising category of anti-HIV drugs which may offer significant benefits in both safety and efficacy versus currently available HIV therapies.

The development programs for PRO 542 and PRO 140 were described in an invited talk delivered by William C. Olson, PhD, Progenics. Included in the presentation were new findings on the sequence of molecular events that enable PRO 542, PRO...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2000-12-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry